Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or… | Phase 2 | terminated | Oct 2, 2014 | SCRI Development Innovations, LLC | Safety lead-in data did not support continuation of study. | Safety / toxicity |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | Phase 2 | withdrawn | Mar 30, 2015 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | Phase 1 | terminated | Jan 5, 2012 | Georgetown University | Drug no longer available | Other (stated, no rule matched) |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | Phase 2 | withdrawn | Jun 19, 2014 | Abramson Cancer Center at Penn Medicine | Did not enroll | Enrollment / accrual |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous… | Phase 2 | terminated | Apr 14, 2014 | SCRI Development Innovations, LLC | Closed early due to slow accrual. | Enrollment / accrual |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated,… | Phase 2 | terminated | Jul 7, 2011 | University of Michigan Rogel Cancer Center | Bexxar isn't being produced by the manufacturer as of Feb. 2014 | Drug supply |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular… | Phase 3 | terminated | Apr 15, 2015 | Boehringer Ingelheim | not stated | Not stated |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | Phase 2 | terminated | Jan 12, 2004 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | Phase 2 | withdrawn | Oct 16, 2015 | University of Arkansas | Investigator decided to close study without enrollment | Investigator |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients…(MM) | Phase 4 | withdrawn | Aug 5, 2011 | DFINE Inc. | not stated | Not stated |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma… | N/A | terminated | Apr 26, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual, loss of sponsor support | Enrollment / accrual |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV… | Phase 2 | terminated | Sep 27, 2012 | Oncotherapeutics | Terminated by Sponsor of this study. | Other (stated, no rule matched) |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic… | Phase 2 | terminated | May 2, 2014 | National Cancer Institute (NCI) | Slow accrual. | Enrollment / accrual |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin… | Phase 1 | terminated | Dec 15, 2009 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | Phase 2 | terminated | Jul 10, 2012 | Adam Lerner | Poor enrollment | Enrollment / accrual |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | — | terminated | Sep 20, 2013 | Celgene | Business Decision | Sponsor / business decision |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in… | Phase 2 | terminated | May 8, 2015 | Dana-Farber Cancer Institute | Safety issues from trials in CLL | Safety / toxicity |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | Phase 4 | withdrawn | Jul 1, 2015 | Jun Zhu | not stated | Not stated |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously…(CARAMEL 2) | Phase 2 | withdrawn | Mar 18, 2013 | Mayo Clinic | not stated | Not stated |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | Phase 1 | terminated | Mar 16, 2012 | Washington University School of Medicine | completed accrual to phase I but drug did not show activity, so halted before initiation of phase II | Enrollment / accrual |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With… | Phase 1 / Phase 2 | withdrawn | Sep 27, 2005 | Stanford University | not stated | Not stated |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Phase 1 | withdrawn | May 2, 2016 | Anne Beaven, MD | Boehringer Ingelheim is discontinuing their volasertib development program | Other (stated, no rule matched) |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Sep 17, 2009 | Anne Beaven, MD | The toxicity seemed to outweigh the benefit. | Safety / toxicity |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jan 13, 2016 | Medivation, Inc. | not stated | Not stated |
| NCT01745354 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic… | Phase 1 | terminated | Dec 10, 2012 | Robert Lowsky | Accrual issues - Slow accrual | Enrollment / accrual |
| NCT01704742 | Prospective Study of Lymphoproliferative Diseases | — | withdrawn | Oct 11, 2012 | West Virginia University | Protocol not considered a clinical trial for registration purposes; no subjects enrolled to date… | Enrollment / accrual |
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed…(PANORAMA-5) | Phase 2 | withdrawn | Apr 29, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00255684 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and… | N/A | terminated | Nov 21, 2005 | University of Rochester | low accrual | Enrollment / accrual |
| NCT01423539 | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed… | Phase 2 | withdrawn | Aug 26, 2011 | Genentech, Inc. | The NAVIGATE study has been terminated due to non-safety related reasons. | Safety / toxicity |
| NCT01609036 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular… | — | terminated | May 31, 2012 | Hoffmann-La Roche | not stated | Not stated |
| NCT01724294 | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP… | — | terminated | Nov 9, 2012 | Hoffmann-La Roche | not stated | Not stated |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to… | Phase 2 | terminated | Dec 25, 2013 | Attaya Suvannasankha | Slow accrual | Enrollment / accrual |
| NCT01541072 | Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After…(PALM2) | N/A | terminated | Feb 29, 2012 | Centre Leon Berard | Number of enrolled patients was insufficient during planned inclusion time. | Enrollment / accrual |
| NCT02115126 | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell… | Phase 2 | withdrawn | Apr 15, 2014 | David Rizzieri, MD | not stated | Not stated |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin… | Phase 2 | terminated | Aug 23, 2010 | Hoosier Cancer Research Network | Slow accrual | Enrollment / accrual |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients… | Phase 2 | terminated | Jun 15, 2010 | Hoffmann-La Roche | not stated | Not stated |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | Phase 2 | terminated | Oct 3, 2012 | Greg Monohan | Research cancelled following interim analysis | Efficacy / futility |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Nov 11, 2008 | Royal Marsden NHS Foundation Trust | Toxicity and efficacy data from another trial | Safety / toxicity |
| NCT01188915 | Personalised Program for Women Treated for Hodgkin Disease(PROPER) | N/A | terminated | Aug 26, 2010 | Institut Paoli-Calmettes | Sponsor decision | Sponsor / business decision |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple… | Phase 1 | terminated | Jun 3, 2009 | Cougar Biotechnology, Inc. | Terminated early due to lack of clinical response. | Other (stated, no rule matched) |
| NCT02141100 | Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of… | Phase 1 / Phase 2 | withdrawn | May 19, 2014 | Kjeld Schmiegelow | not stated | Not stated |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in… | Phase 1 / Phase 2 | withdrawn | Nov 16, 2015 | Bayer | Study restarted under new study number 18987 | Other (stated, no rule matched) |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | N/A | terminated | Aug 26, 2011 | Merck KGaA, Darmstadt, Germany | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01598558 | Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using… | N/A | withdrawn | May 15, 2012 | Sanjiv Sam Gambhir | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic… | Phase 2 | terminated | Jan 18, 2006 | German CLL Study Group | slow recruitment | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | Phase 2 | terminated | Oct 12, 2015 | Henrik Gregersen | Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide… | Other (stated, no rule matched) |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 | terminated | Nov 15, 2013 | M.D. Anderson Cancer Center | Terminated Phase I due to slow accrual without progression to Phase II. | Enrollment / accrual |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone… | Phase 2 | terminated | May 12, 2010 | Duke University | The study closed temporarily in February 2012 pending analysis of samples collected. In October,… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 16, 2017source: clinicaltrials